TIVC

Tivic Health Systems, Inc. is a late-stage therapeutics company. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. It has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The Company offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.

Wall Street analysts forecast TIVC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIVC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tivic Health Systems Inc revenue for the last quarter amounts to 146.00K USD, increased 15.87 % YoY.

Tivic Health Systems Inc. EPS for the last quarter amounts to -1.97 USD, decreased -49.87 % YoY.

Tivic Health Systems Inc (TIVC) has 7 emplpoyees as of January 10 2026.

Today TIVC has the market capitalization of 3.41M USD.